Axon Sports

Axonics to Participate in November Investor Conferences

Retrieved on: 
Wednesday, November 1, 2023
Health, Health Technology, Axon Sports, Dietary supplement

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the following investor conferences in November:

Key Points: 

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the following investor conferences in November:

Axonics to Participate in September Investor Conferences

Retrieved on: 
Friday, August 25, 2023
Biotechnology, Medical Devices, Other Health, Health, Health Technology, Axon Sports, Dietary supplement

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the following investor conferences in September:

Key Points: 

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the following investor conferences in September:

Axonics to Participate in Upcoming Investor Conferences

Retrieved on: 
Tuesday, April 25, 2023
Pharmaceutical, Health, Medical Devices, Axon Sports, Dietary supplement

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the following upcoming investor conferences:

Key Points: 

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the following upcoming investor conferences:

Axonics Acquires Technology to Facilitate Easier and Faster Placement of Implantable Leads for Sacral Neuromodulation

Retrieved on: 
Monday, April 24, 2023
Pharmaceutical, Health, Medical Devices, Anatomy, Physician, Learning curve, SNM, PNE, Acquisition, Patient, Fluoroscopy, FDA, Sacrum, Software, Medical imaging, Radian, Axon Sports

Physicians determine a patient’s eligibility for long-term SNM therapy by performing an external trial or peripheral nerve evaluation (PNE).

Key Points: 
  • Physicians determine a patient’s eligibility for long-term SNM therapy by performing an external trial or peripheral nerve evaluation (PNE).
  • The temporary lead that is placed during a PNE is often done in the office setting without real-time imaging (i.e., fluoroscopy).
  • The acquired technology addresses this challenge with an elegant solution comprising a software application and a hardware tool that makes PNE lead placement easier, faster, and more accurate.
  • We are confident that empowering physicians with innovative technology and tools has the potential to drive significant SNM market expansion in the years ahead.”

EQS-News: Ahead of its business plan, Andera Partners approaches 4 billion euros in assets under management and announces a new 2028 target of 6 to 8 billion euros

Retrieved on: 
Wednesday, February 22, 2023
ERI, Climate change, Senior advisor, Terra, Axon Sports, Investment, Partnership, HR, Acquisition, Carbon, Andera-ye Olya, CSR, ACB, Therapy, Risk, Biodiversity, IPO, TBS, Partner, Health, Growth, Tricare, Russell Targ, Success, Tourism, Renewable energy, Cryptocurrency, Asset management, Fine chemical, Elan

Ahead of its business plan, Andera Partners approaches 4 billion euros in assets under management and announces a new 2028 target of 6 to 8 billion euros

Key Points: 
  • Ahead of its business plan, Andera Partners approaches 4 billion euros in assets under management and announces a new 2028 target of 6 to 8 billion euros
    The issuer is solely responsible for the content of this announcement.
  • With more than 3.7bn€ in assets under management, Andera Partners is quickly reaching its 2025 target of 4 to 5bn€ under management and announces a new target of 6 to 8bn€ by 2028.
  • Ahead of its business plan, Andera Partners will reach 4bn€ in assets under management in 2023, thus achieving its initial 2025 target two years ahead of schedule.
  • In announcing a new target of 6 to 8bn€ in assets under management by 2028, Andera Partners outlines its ambitions for the next five years.

SoniVie Raises $60m in Round C Financing, and Appoints New Board Members

Retrieved on: 
Monday, January 9, 2023
The Company, TEL, Stroke, Kidney failure, Medtech, Risk, Patient, Hypertension, Renal artery, Axon Sports, Physician, Therapy, Blood pressure, Pharmaceutical industry, Wiśniewski

TEL AVIV, Israel, Jan. 9, 2023 /PRNewswire/ -- SoniVie Ltd. ("SoniVie" or the "Company"), a medical device company developing a proprietary solution to treat hypertension, announced today the completion of a $60 million series C round financing. The financing was led by Andera Partners, with participation from Supernova Invest and Omega Funds. Current SoniVie shareholder TechWald also participated.

Key Points: 
  • In conjunction with the financing, the Company appointed two renowned medtech experts to its Board of Directors, Raymond W. Cohen and Zeev Zehavi, as independent directors.
  • The proceeds from SoniVie financing are envisioned to be used to reach clinical and regulatory milestones and to support TIVUS™ renal artery denervation program.
  • Raphaël Wisniewski of Andera Partners commented, "SoniVie TIVUS™ has the potential to provide patients and physicians with a safe, efficient and easy to use device.
  • We are thrilled to support this talented management together with our syndicate partners and our new board members".

SoniVie Raises $60m in Round C Financing, and Appoints New Board Members

Retrieved on: 
Monday, January 9, 2023
The Company, TEL, Stroke, Kidney failure, Medtech, Risk, Patient, Hypertension, Renal artery, Axon Sports, Physician, Therapy, Blood pressure, Pharmaceutical industry, Wiśniewski

TEL AVIV, Israel, Jan. 9, 2023 /PRNewswire/ -- SoniVie Ltd. ("SoniVie" or the "Company"), a medical device company developing a proprietary solution to treat hypertension, announced today the completion of a $60 million series C round financing. The financing was led by Andera Partners, with participation from Supernova Invest and Omega Funds. Current SoniVie shareholder TechWald also participated.

Key Points: 
  • In conjunction with the financing, the Company appointed two renowned medtech experts to its Board of Directors, Raymond W. Cohen and Zeev Zehavi, as independent directors.
  • The proceeds from SoniVie financing are envisioned to be used to reach clinical and regulatory milestones and to support TIVUS™ renal artery denervation program.
  • Raphaël Wisniewski of Andera Partners commented, "SoniVie TIVUS™ has the potential to provide patients and physicians with a safe, efficient and easy to use device.
  • We are thrilled to support this talented management together with our syndicate partners and our new board members".

EQS-News: Andera Partners invests in SoniVie, a medtech company developing a promising device for the treatment of hypertension

Retrieved on: 
Sunday, January 22, 2023
The Company, TEL, Stroke, Kidney failure, Medtech, Risk, Partner, Patient, Hypertension, Renal artery, Physician, Therapy, Blood pressure, Pharmaceutical industry, Wiśniewski, Axon Sports

TEL AVIV, ISRAEL, AND PARIS, FRANCE, JANUARY 10, 2023 -- SoniVie Ltd. ("SoniVie" or the "Company"), a medical device company developing a proprietary solution to treat hypertension, announced today the completion of a $60 million series C round financing. The financing was led by Andera Partners, with participation from Supernova Invest and Omega Funds. Current SoniVie shareholder TechWald also participated.

Key Points: 
  • Andera Partners invests in SoniVie, a medtech company developing a promising device for the treatment of hypertension
    The issuer is solely responsible for the content of this announcement.
  • The financing was led by Andera Partners, with participation from Supernova Invest and Omega Funds.
  • Raphaël Wisniewski of Andera Partners commented, "SoniVie TIVUS™ has the potential to provide patients and physicians with a safe, efficient and easy to use device.
  • We are thrilled to support this talented management together with our syndicate partners and our new board members".

EQS-News: Andera Partners raises its largest life sciences fund at €456M, demonstrating the attractiveness of its activity and of the sector

Retrieved on: 
Monday, October 10, 2022
Well, EQS, Insurance, CSR, Goal, Therapy, SFDR, Article, Growth, Acceleration, Partner, Patient, Climate, Investment, Partnership, Lists of publishing companies, Industry, Russell Targ, United, News, Axon Sports, DNA, Article 8 of the European Convention on Human Rights, Financial services, Security (finance), Pharmaceutical industry, Andera-ye Olya

Andera Partners raises its largest life sciences fund at 456M, demonstrating the attractiveness of its activity and of the sector

Key Points: 
  • Andera Partners raises its largest life sciences fund at 456M, demonstrating the attractiveness of its activity and of the sector
    The issuer is solely responsible for the content of this announcement.
  • Andera Partners raises its largest life sciences fund at 456M, demonstrating the attractiveness of its activity and of the sector
    PARIS, 10 OCTOBER 2022 Andera Life Sciences, the business line specialising in innovative therapeutics and medical technologies of the asset management company Andera Partners, has announced the finalisation of its fundraising for its BioDiscovery 6 fund at 456 million euros.
  • The sixth generation of BioDiscovery funds is consolidating Andera Partners position as one of the leading players in life sciences venture capital in Europe.
  • Its teams manage over 3.6 billion in investments in life sciences (Andera Life Sciences), growth and buyout capital (Andera MidCap, Andera Expansion, Andera Co-Invest), sponsorless transactions (Andera Acto) and ecological transition (Andera Infra).

Nyxoah Nominates Raymond Cohen and Virginia Kirby for Appointment to Its Board of Directors

Retrieved on: 
Friday, May 6, 2022
DREAM, Orbital Technologies Commercial Space Station, CCC, Sleep, Euronext, University, Senior, Medtronic, Nasdaq, CET, BLAST, NASDAQ, EV3, NYSE, Company, OSA, 3M, Mont-Saint-Guibert, Patient, FDA, CE, Obstructive sleep apnea, Leadership, Sleep disorder, European, Axon Sports, IDE, CEO, Mentorship, Boston Scientific, Pharmaceutical industry

Mr. Deyo has served on Nyxoahs board since 2016 and Mr.Janssen since 2018.

Key Points: 
  • Mr. Deyo has served on Nyxoahs board since 2016 and Mr.Janssen since 2018.
  • Mr. Cohen has served as Chief Executive Officer and board member of Axonics, Inc. (Nasdaq: AXNX) since co-founding the company in 2013.
  • From 2010 to 2012, he served as CEO of Vessix Vascular, a venture capital-backed renal denervation company that was acquired by Boston Scientific in November 2012.
  • Currently, Mr. Cohen serves as the Chairman of the board of directors at BioVentrix Inc., a privately-held transcatheter ventricular restoration company.